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Modeling ErbB2-p130Cas 
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The ErbB2 receptor tyrosine kinase is overexpressed in approximately 15–20% of breast tumors and 
associated with aggressive disease and poor clinical outcome. p130Cas represents a nodal scaffold 
protein regulating cell survival, migration and proliferation in normal and pathological contexts. 
p130Cas overexpression in ErbB2 human breast cancer correlates with poor prognosis and metastasis 
formation. Recent data indicate that p130Cas association to ErbB2 protects ErbB2 from degradation, 
thus enhancing tumorigenesis. Therefore, inhibiting p130Cas/ErbB2 interaction might represent a new 
therapeutic strategy to target breast cancer. Here we demonstrate by performing Molecular Modeling, 
Molecular Dynamics, dot blot, ELISA and fluorescence quenching experiments, that p130Cas binds 
directly to ErbB2. Then, by structure-based virtual screening, we identified two potential inhibitors of 
p130Cas/ErbB2 interaction. Their experimental validation was performed in vitro and in ErbB2-positive 
breast cancer cellular models. The results highlight that both compounds interfere with p130Cas/
ErbB2 binding and significantly affect cell proliferation and sensitivity to Trastuzumab. Overall, this 
study identifies p130Cas/ErbB2 complex as a potential breast cancer target revealing new therapeutic 
perspectives for protein-protein interaction (PPI).
Breast cancer is the second most common cancer worldwide after lung cancer, the fifth most common cause of 
cancer death, and the leading cause of cancer death in women1.
In the last decades breast cancer treatment has greatly improved due to the development of targeted thera-
pies against Receptor Tyrosine Kinases (RTKs) whose hyperactivation or overexpression leads to increased cell 
proliferation, survival and transformation2. In particular, there is a huge interest among medicinal chemists for 
inhibitors of the epidermal growth factor receptor (EGFR) family which includes four structurally related recep-
tor tyrosine kinases (ErbB1-4). The ErbB proteins function as homo- and hetero- dimerizer upon ligand binding, 
but ErbB2 is an orphan receptor and its activation upon homo- and hetero- dimerization is ligand-independent. 
Notably, over-expression or amplification of ErbB2 tyrosine kinase occurs in up to 20% of human breast cancers, 
where it is predictive of aggressive disease and poor clinical outcome3. Several anti-ErbB2 therapies have been 
recently proposed including receptor tyrosine kinase inhibitors and humanized monoclonal antibodies. Among 
them, Trastuzumab was approved for the treatment of breast cancers overexpressing ErbB2, alone or in combina-
tion with standard chemotherapy. The mechanism of action of Trastuzumab is complex and not well understood, 
resulting in modest downregulation of the ErbB2 receptor4,5.
p130Cas is an adaptor protein devoid of any enzymatic or transcriptional activity and its modular structure 
with various binding motifs allows the formation of multi-protein signaling complexes. This results in the induc-
tion and/or maintenance of signaling pathways with pleiotropic effects on cell motility, cell adhesion, cytoskel-
eton remodeling, invasion, survival and proliferation. The relevance of p130Cas adaptor protein in cancer has 
been extensively supported. p130Cas overexpression has been detected in human breast, prostate, ovarian, 
lung, colorectal, pancreatic and hepatocellular carcinoma, as well as in glioma, melanoma, anaplastic large cell 
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lymphoma and chronic myelogenous leukemia, although the exact mechanisms that drive p130Cas overexpres-
sion in cancer have not yet been identified6–8.
Specifically, in ErbB2-positive breast cancer, p130Cas overexpression correlates with poor prognosis and 
increase metastatization9. From a molecular point of view, it has been demonstrated that p130Cas is a crucial 
component of a functional molecular complex consisting in ErbB2, c-Src, and FAK supporting cell proliferation 
and invasion10. Recently, it was reported that p130Cas is able to stabilize ErbB2, by binding and protecting it from 
autophagic degradation. Indeed, p130Cas binding to ErbB2 does not allow the association of CHIP and Cbl, the 
major E3 ubiquitin ligases binding ErbB2, possibly through steric hindrance5.
These data also indicate that high levels of p130Cas expression inversely correlate with ErbB2 sensitivity to 
Trastuzumab. The mechanism through which p130Cas mediates resistance to Trastuzumab might rely on the 
increased ErbB2 stability to the cell membrane. This increased stabilization of ErbB2 by p130Cas might be the 
crucial event driving breast cancer progression and resistance, strengthening the relevance of p130Cas as putative 
therapeutic target to overcome resistance to Trastuzumab5.
In addition, alternative ErbB2 targeted therapies, such as Pertuzumab or Trastuzumab-Emtansine (T-DM1) 
were developed. Combination of Trastuzumab and Pertuzumab treatment have shown a statistically significant 
increase in overall survival of ErbB2 positive metastatic breast cancer patients11,12, while T-DM1 improved overall 
survival of ErbB2-positive metastatic patients that failed other ErbB2-targeted drugs13.
Even though these therapies extend overall survival in responders, a high percentage of patients develop 
resistance. Indeed, Trastuzumab/Pertuzumab/Docetaxel versus Trastuzumab/Docetaxel combination treatment 
increased the patients’ responsiveness from 29% to 45.8%14, while T-DM1 failed to induce response in 57% of 
patients15.
Therefore, alternative strategies are needed. Tyrosine kinase inhibitors (TKI) have been proposed as alterna-
tive treatments to counteract Trastuzumab resistance, but they have some limitations. The most critical drawback 
is the development of drug resistance due to secondary mutations of the targeted receptors or to compensatory 
activation of other RTKs that renders the therapies ineffective.
Consequently, key protein-protein interactions involved in RTKs signaling could represent a major source of 
novel pharmacological targets. In contrast to enzyme inhibitors (es. TKI), protein-protein interaction inhibitors 
target larger contact surface often involving more than two contact pockets composed of multiple amino acids 
located in different region of the protein16,17. This in turn, should limit or delay development of drug resistance 
due to secondary mutation of the targeted receptor.
Taken together this evidence suggests important therapeutic and translational applications of p130Cas in 
ErbB2 breast cancer and supports the hypothesis that p130Cas/ErbB2 interaction can serve as a potential target 
for the discovery and development of new anticancer agents, that can be used in combination with standard ther-
apy to manage and control Trastuzumab resistance.
To verify this hypothesis, we have initially used computer strategies, in vitro proteomic approach and cellular 
models and showed that the SH3 domain of p130Cas binds a specific sequence of ErbB2 intracellular domain. 
Then, a structure-based virtual screening (SBVS) procedure identified molecules with potential inhibitory activity 
vs p130Cas/ErbB2 interaction. Two ad hoc selected hits resulting from the computational screening were experi-
mentally tested both in vitro and in breast cancer cell lines. Finally, the physico-chemical and ADME-Tox profiles 
of the two molecules were predicted to exploit their full potential as drugs.
Overall this study supports p130Cas/ErbB2 complex as a potential breast cancer target and shows the drug-
gability of this protein-protein interaction (PPI) that might benefit of a more advanced optimization effort for 
therapeutic applications.
Results
Modeling the interaction of p130Cas and ErbB2. Literature analysis suggests that p130Cas scaffold 
might independently associate with ErbB2 in a direct way. Due to the structural complexity of the partners, the 
study focused only on the interaction region between the two proteins. Therefore, we searched for protein-protein 
binding sequences on ErbB2 cytosolic portion by the online algorithm Eukaryotic Linear Motif (ELM) (www.elm.
eu). ELM is a bioinformatic resource combining experimental evidences with a predictive algorithm that returns 
the biological function (experimentally determined if possible or predicted) of recognized short sequences in 
eukaryotic proteins18.
The ELM sequence analysis of C-terminal cytosolic domain of ErbB2 predicts the presence in position 1145–
1153 of a -V[RPQPPSP]R- nine amino acid sequence (PPII_ErbB2). The motif is a polyproline type II domain, 
i.e. a left hand, trans proline coil whose 1-4-7 residue-side chains have the same spatial orientation (RxxPxxP) 
and could act as a binding site for the SH3 domain of p130Cas (Fig. 1A)19–21. On the basis of these evidences, an 
in-silico interaction model of the PPII_ErbB2 peptide and p130Cas SH3 domain (SH3_p130Cas) was thus built 
using a template-based modeling strategy22. The structure of the SH3 domain of p130Cas was downloaded from 
the PDB (PDB code 1WYX, resolution = 1.1 Å)23. PPII_ErbB2 was modeled using the crystallographic structure 
of the complex between PD1R, a synthetic peptide with polyproline type II conformation, and the SH3 domain 
of p85 subunit of PI3K (highly homologous to SH3_p130Cas) (PDB code 3I5R, resolution 1.7 Å). The interaction 
model (see Experimental Section) shows three contact regions (named 1, 2 and 3 in Fig. 1B): the first concerns 
PPII_ErbB2 Arg2 that interacts with SH3_p130Cas Glu15 and Glu19 and forms a network of reinforced hydro-
gen bonds, the second and the third are hydrophobic interactions involving Pro5 and Pro8 (PPII_ErbB2) and 
apolar pockets of SH3_p130Cas.
Molecular Dynamics (MD) simulations. MD simulations were performed to check the stability over the 
time of the interaction described above. Results are resumed in Fig. 1C which shows the energy variation with 
the time (t). No dissociation of the SH3_p130Cas/PPII_ErbB2 complex is observed. As a negative control we 
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mutated the three PPII residues mainly involved in the interaction into amino acids less prone to stabilize the 
binding (positive charged Arg2 into negative charged Glu, small Pro5 and Pro8 into the larger Asn) and applied 
the same MD protocol. Results show a weaker interaction between the mutated peptide and SH3_p130Cas (see 
Fig. S1 in Supporting Information).
Furthermore, MD simulations were also successfully used to support the binding orientation, – VRPQPPSPR – 
of the SH3 domain to the polyproline domain (see Fig. S2 in Supporting Information).
In vitro validation of the direct interaction between SH3 domain of p130Cas and ErbB2. We 
expressed and purified recombinant proteins for p130Cas and ErbB2 as described in the Experimental Section 
Figure 1. Modeling of SH3_p130Cas/PPII_ErbB2 interaction. (A) Schematic representation of the ErbB2 
receptor. The class I SH3 ligand in position 1146–1152 shown in the inset is located in the unstructured 
carboxy-terminal portion of ErbB2 receptor. (B) PPII_ErbB2 peptide is shown in green, hydrophobic 
and positive charge interaction surfaces are in grey, negative charge interaction surfaces in cyan. The three 
interaction sites (1, 2 and 3) are circled in white. The PPII_ErbB2 Arg2, Pro5 and Pro8 side-chains are 
highlighted in green. Interacting residues for SH3_p130Cas are described in the text. (C) Not standard 
conditions stages (black dots), standard condition stages (light blue dots), Uab trend line (green), SH3_p130Cas 
(blue chain), PPII_ErbB2 (red chain). This is shown by the four snapshots in Fig. 2 that represent four dynamics 
stages distributed along the simulation (standard conditions P [90;110] kPa and T [230;310] K). Stage 2 
represents a “peak” in the trend of Uab values; it has been chosen to demonstrate that this Uab variation does not 
lead to the dissociation of the complex. Apart from stage 2 (and stage 0, the starting point from SH3_p130Cas/
PPII_ErbB2 interaction model) no substantial variation in the Uab general trend values were observed, 
suggesting that there is no difference in complex stability between each couple of stages.
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and Table 1 (see Fig. S3 in Supporting Information). Three domains of p130Cas, i.e. the SH3 domain (SH3), 
the substrate domain (YXXP) and the carboxy-terminal domain (CT), were tested for their ability to bind two 
recombinant proteins for the C-terminal tail of ErbB2 (MBP_shortPPII_ErbB2 and MBP_longPPII_ErbB2, see 
Table 1), containing the putative polyproline type II sequence, in two different in vitro assays.
As shown in Fig. 2A, dot blot assays were performed by spotting the GST-tagged p130Cas domains on nitro-
cellulose membrane and probing them with MBP_shortPPII_ErbB2. Western blot analysis clearly revealed that 
the interaction between SH3_p130Cas and shortPPII_ErbB2 was specific as no binding was observed with other 
p130Cas domains (Fig. 2A).
As a further validation of the SH3_p130Cas/PPII_ErbB2 interaction, in vitro binding assays were performed. 
GST- and MBP- tagged recombinant proteins were kept in solution overnight at 4 °C and then immunoprecipi-
tated with anti-MBP antibody. Western blot analysis indicates that the interaction between p130Cas and ErbB2 
indeed occurred through the SH3 domain of p130Cas (Fig. 2B).
To quantify the entity of the interaction, we performed a fluorescence assay. As shown in Fig. 2C an increas-
ing concentration of MBP_shortPPII_ErbB2 causes an enhancement in fluorescence intensity emission of 
Figure 2. SH3_p130Cas directly interacts with shortPPII_ErbB2 and longPPII_ErbB2 in vitro. (A) Dot blot 
experiment revealed a direct interaction between GST_SH3_p130Cas and MBP_shortPPII_ErbB2 (lane 1–2), 
using anti-MBP antibody. No interactions were detected with control GST_ctrl, GST_YXXP_p130Cas and 
GST_CT_p130Cas recombinant proteins (lane 3–5). Normalization was performed with anti-GST antibody. (B) 
GST_SH3_p130Cas was able to interact with MBP_shortPPII_ErbB2 and MBP_longPPII_ErbB2 in solution 
(lane 2 and 6). After standard immunoprecipitation with anti-MBP antibody, the interaction was revealed with 
anti-GST antibody. No interaction or little aspecific interaction were detected with control GST_ctrl (lane 1 
and 5), GST_YXXP_p130Cas (lane 3 and 7) and GST_CT_p130Cas (lane 4 and 8) recombinant proteins. (C) 
Enhancement fluorescence of Fl-GST_SH3_p130Cas (3.0 μM) in presence of increasing concentrations of 
MBP_shortPPII_ErbB2 (0,05, 0.1, 0.3,0.75, 1, 2, 3 µM).
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Fl-GST_SH3_p130Cas. Fluorescence data were analyzed with a nonlinear least-squares fit (Fig. S4a) and pro-
duced a Kd = 4.07 × 10−8 M, a value that could be ascribed to a moderate-strength interaction.
Overall in vitro assays demonstrated that p130Cas can effectively bind ErbB2 receptor in a direct way, and that 
this association is mediated by the SH3 domain of p130Cas.
Validation of key aminoacids involved in p130Cas/ErbB2 interaction. To avoid false positive 
results due to the incorrect folding of proteins expressed in bacteria, we validated the p130Cas/ErbB2 interaction 
in 293T mammalian cell line that express normal levels of p130Cas but no detectable expression levels of ErbB2. 
We cloned and transfected plasmids containing GFP-tagged version of ErbB2 recombinant proteins (GFP_short-
PPII_ErbB2 and GFP_longPPII_ErbB2) as described in the Experimental Section. Five days after transfection, 
standard co-immunoprecipitation was performed using anti-p130Cas mouse antibody. GFP-tagged ErbB2 con-
structs co-immunoprecipitated with endogenous p130Cas in 293T cell line and thus false positive results due to 
the misfolding of recombinant proteins were excluded (Fig. 3A).
To verify in a cellular model that the interaction between p130Cas and ErbB2 occurs between p130Cas SH3 
domain and the PPII domain of ErbB2, mutagenesis experiments were performed by modifying key residues 
of the polyproline type II motif of ErbB2. Specifically, cationic Arg2 was mutated to the anionic residue Asp; 
Pro5 and Pro8 were mutated to Ala. Proline is unique among the 20 common amino acids in having its side 
chain cyclized onto the backbone nitrogen atom, conferring it special chemical and physical characteristics that 
cannot be mimic by other amino acids24. Pro-Ala substitution was chosen to at least partially maintain the little 
size and the hydrophobic interactions of proline residue. We also generated a mutant in which the PPII domain 
of ErbB2 was completely deleted (named “deleter”) to assess if this motif was essential to drive p130Cas/ErbB2 
interaction. Four different mutants for GFP_shortPPII_ErbB2 were generated as described in the Experimental 
Section to perform co-immunoprecipitation in 293T cell line (Fig. 3B). The same mutants were also produced as 
MBP-tagged recombinant proteins to perform an in vitro ELISA direct binding assay (Fig. 3C).
Both experiments show that mutagenesis of key residues in PPII_ErbB2 sequence alters its binding to SH3 
domain of p130Cas. Interestingly, the substitution of Pro5 and Pro8 to Ala strongly affects the amount of binding, 
while the substitution of Arg to Asp does not impair the binding suggesting that the reinforced hydrogen bond 
plays a minor role in the interaction. On the contrary, mutation and/or deletion of the core PxxP motif (either by 
Proline substitution or by complete deletion of the PPII motif) strongly reduced SH3_p130Cas/shortPPII_ErbB2 
ErbB2
PPII_ErbB2
Polyproline domain type II identified in ErbB2 protein sequence by ELM algorithm.
Sequence: V[RPQPPSP]R
Position: 1145–1153 in the ErbB2 protein sequence (Isoform 1, identifier: P04626-1).
MBP_longPPII_ErbB2
Recombinant protein containing an N-terminal MBP tag followed by a fragment of ErbB2 cytosolic 
portion (aminoacids 1103–1255). This fragment starts 30 aminoacids before the putative polyproline 
domain (PPII_ErbB2) and ends 30aa after.
MBP_shortPPII_ErbB2
Recombinant protein containing an N-terminal MBP tag followed by a fragment of ErbB2 cytosolic 
portion (aminoacids 1103–1194). This fragment starts 30 aminoacids before the putative polyproline 
domain (PPII_ErbB2) and ends with the endogenous C-terminal of the protein.
MBP_ctrl MBP tag (Maltose Binding Protein from E. Coli) used as affinity purification tag for ErbB2 recombinant constructs. MPB protein alone was used as control.
MBP_R → D_shortPPII_ErbB2
This recombinant protein was generated from MBP_shortPPII_ErbB2 by site-directed mutagenesis.
It carries an Arginine to Aspartate (R to D) substitution at position 44 (position 1146 in the original ErbB2 
sequence). This substitution alters the putative polyproline domain identified in ErbB2 protein sequence 
from V[RPQPPSP]R to V[DPQPPSP]R.
MBP_PP → AA_
shortPPII_ErbB2
This recombinant protein was generated from MBP_shortPPII_ErbB2 by site-directed mutagenesis.
It carries two Proline to Alanine (P to A) substitutions at position 47 and 50 (position 1149 and 1152 
in the original ErbB2 sequence). These substitutions alter the putative polyproline domain identified in 
ErbB2 protein sequence from V[RPQPPSP]R to V[RPQAPSA]R.
MBP_RPP → DAA_
shortPPII_ErbB2
This recombinant protein was generated from MBP_shortPPII_ErbB2 by site-directed mutagenesis.
It carries an Arginine to Aspartate (R to D) substitution at position 44 (position 1146 in the original ErbB2 
sequence) and two Proline to Alanine (P to A) substitutions at position 47 and 50 (position 1149 and 1152 
in the original ErbB2 sequence). These substitutions alter the putative polyproline domain identified in 
ErbB2 protein sequence from V[RPQPPSP]R to V[DPQAPSA]R.
MBP_deleter_shortPPII_ErbB2
This recombinant protein was generated from MBP_shortPPII_ErbB2 by site-directed mutagenesis.
This protein carries a 7-aminoacid deletion from position 44 to 50 (position 1146–1152 in the original 
ErbB2 sequence). This deletion abrogates the putative polyproline domain identified in ErbB2 protein 
sequence.
p130Cas
GST_SH3_p130Cas Recombinant protein containing an N-terminal GST tag followed by a fragment of p130Cas protein (aminoacids 3–71). This fragment represents the SH3 domain of p130Cas as described in23.
GST_YXXP_p130Cas
Recombinant protein containing an N-terminal GST tag followed by a fragment of p130Cas protein 
(aminoacids 80–400). This fragment represents a large central substrate domain composed of 15 repeats of 
a four amino acid sequence (YXXP)23.
GST_CT_p130Cas
Recombinant protein containing an N-terminal GST tag followed by a fragment of p130Cas protein 
(aminoacids 654–874). This fragment represents the carboxy-terminal (CT) domain of p130Cas which 
possess consensus binding sites for the SH2 and SH3 domains of Src23.
GST_ctrl GST tag (Glutathione S-Transferase from Schistosoma japonicum) used as affinity purification tag for p130Cas recombinant constructs. GST protein alone was used as control.
Table 1. List of constructs used.
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Figure 3. Validation of p130Cas/ErbB2 direct interaction in 293T cell line. (A) 293T cells were transfected with 
GFP-tagged constructs for shortPPII_ErbB2 and longPPII_ErbB2. Five days after transfection, endogenous 
p130Cas was immunoprecipitated with anti-p130Cas antibody. Interacting proteins were detected with anti-
GFP antibody. Endogenous p130Cas interacts with both GFP_shortPPII_ErbB2 and GFP_longPPII_ErbB2, 
although little aspecific interaction was detected with control GFP_ctrl (left). Total cell extracts were blotted 
with anti-p130Cas and anti-GFP antibodies to assess transfection efficiency (right). (B) 293T cells were 
transfected with mutant forms of GFP_shortPPII_ErbB2. Five days after transfection, endogenous p130Cas 
was immunoprecipitated with anti-p130Cas antibody. Interactions were revealed using anti-GFP antibody 
(left). Mutation of the cationic residue Arg2 slightly reduced GFP_shortPPII_ErbB2 binding to endogenous 
p130Cas; conversely, mutations affecting Pro5 and Pro8 markedly decreased their association, as well as 
deletion of the PPII motif. Total cell extracts were blotted with anti-p130Cas and anti-GFP antibodies to 
assess mutants expression (right). (C) ELISA direct binding assay recapitulated results obtained using Co-
Immunoprecipitation experiments in 293T cell line. Mutation of the cationic residue Arg2 does not affect the 
binding of MBP_shortPPII_ErbB2 to GST_SH3_p130Cas; conversely, mutations affecting Pro5 and Pro8 
markedly decreased their association, as well as deletion of the PPII motif. Data are represented as mean ± SD. 
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association, in vitro and in cellular model, demonstrating the importance of PPII located residues as suggested by 
the in-silico molecular model.
The same strategy was used to validate the PPII-binding pockets in the SH3 domain of p130Cas. Three 
SH3-mutants carrying mutations in the three main sites of the interaction were generated and subjected to an in 
vitro ELISA direct binding assay to evaluate their ability to bind ErbB2 recombinant proteins (Fig. 3D). Aromatic 
residues were changed to alanine to replace bulky hydrophobic residues with small apolar residues (Y10A and 
W41A). In addition, a conserved hydrophilic residue was substituted with a large hydrophobic residue (E15W). 
These mutations involved aminoacids exposed to the solvent on the surface of the SH3 domain and are not impli-
cated in any contacts to main-chain atoms that maintain the structural stability of the SH3 domain25. Notably, all 
SH3 mutants failed to associate with the PPII domain of ErbB2 (Fig. 3D).
Structure-based virtual screening (SBVS). Once validated, the molecular model for p130Cas/ErbB2 
interaction was used to run a SBVS of the ZINC database using FLAP software (see Experimental Section). The 
rational was to find candidates that bind the SH3 domain of p130Cas (SH3_p130Cas) using the same interaction 
pockets used by polyproline ErbB2 sequence (PPII_ErbB2) (see above) thereby inhibiting the binding of ErbB2 
to p130Cas.
Screening results are in Table S2 (Pocket Point Radius = 2 Å), which shows the ten molecules expected to have 
the best capacity to inhibit the SH3_p130Cas/PPII_ErbB2 interaction ranked by their Glob-Prod index (see 
Experimental Section). Potential hits from this SBVS were screening for PAINS using the tool implemented in 
ZINC15 (http://zinc15.docking.org/patterns/home/) to exclude the presence of known classes of assay interfer-
ence groups in 1 and 2.
ZINC84136897 (1) and ZINC39121740 (2) (chemical structures in Fig. 4A) were selected to submit to 
experimental validation. Compound 1 is larger than 2 (MW = 375) and could be described as a urea derivative. 
Compound 2 is a relatively small compound (MW = 226) bearing a sulfonamide group. The choice of these two 
compounds also allows to explore the impact on the inhibitory activity of different binding modes since 1 exploits 
its action by interacting with p130Cas in three regions, whereas the interaction of 2 with p130Cas is driven by 
hydrogen bonding (HB) interactions (Fig. 4B).
In vitro validation of the compounds identified by virtual screening. To experimentally validate the 
binding of compound 1 and 2 on GST_SH3_p130Cas recombinant protein, fluorescence quenching experiments 
were performed.
The fluorescence spectra of Fl-GST_SH3_p130Cas in the absence and in the presence of 1 and 2 at different 
concentrations are shown in Fig. 4C. Fl-GST_SH3_p130Cas shows a strong fluorescence emission at 518 nm and 
its fluorescence intensity decreases gradually with the increase of compound’s concentration. The analysis of equi-
librium dissociation constants showed values with different order of magnitude, KD = 2.0 × 10−7 M for compound 
1 and KD = 5.0 × 10−6 M for compound 2 (Fig. 4C left and right panel, respectively) (see also Fig. S4b,c).
The two compounds were then tested in vitro using a competitive ELISA binding assay, which demonstrated 
their inhibitory activity against the interaction between GST_SH3_p130Cas and MBP_shortPPII_ErbB2 recom-
binant proteins (Fig. 5A). The assay nicely showed reduced interaction between p130Cas and ErbB2 recombinant 
proteins with increasing concentration of tested compounds, while no modulation was revealed with increasing 
concentration of DPN (non-specific control). This experimental evidence validates the SH3 domain of p130Cas as 
possible pharmacological target since its binding to the polyproline domain of ErbB2 is amenable for modulation 
by inhibitory compounds 1 and 2.
As a further confirmation of the 1 and 2 efficacies of inhibiting GST_SH3_p130Cas/MBP_shortPPII_ErbB2 
interaction, fluorescence quenching experiments were performed. As shown in Fig. 5B, compound 1 is more 
efficient in preventing the binding between Fl-GST_SH3_p130Cas and MBP_shortPPII_ErbB2, compared to 
compound 2 (Fig. 5B left and right panel, respectively).
To assess whether these compounds could interfere with p130Cas/ErbB2 association in a cellular con-
text, ErbB2-positive BT474 breast cancer cells were pre-treated for 24 hours with 1 or 2 and subjected to co- 
immunoprecipitation experiments. As shown in Fig. 5C, treatment with selected inhibitory compounds reduced 
the association of p130Cas to ErbB2 also in BT474 breast cancer cells.
Validation in cellular models of the identified inhibitors. In vitro data indicate that compounds 1 and 
2 can interfere with p130Cas/ErbB2 interaction, although with different binding modalities and different affini-
ties. To test which are the consequences of such interference in a cellular context we performed cell proliferation 
and cytotoxicity assays. To this end, BT474 and SKBR3 breast cancer cells were chosen as a suitable experimental 
model as they express high endogenous levels of both ErbB2 and p130Cas5. As shown in Fig. 6A, treatment of 
BT474 cells with serial dilutions of the compounds indicates that compound 1 exhibits toxic effects starting from 
75 μM, while for compound 2 we did not detect cytotoxic effects even at 250 μM. In addition, since we already 
demonstrated that p130Cas/ErbB2 association triggers proliferation of breast cancer cells (as demonstrated by 
soft agar assay in10), a cell proliferation assay was employed to determine EC50 values of 1 and 2 compounds 
**p < 0.01. (D) ELISA direct binding assay was performed with GST_SH3_p130Cas mutants to assess 
their binding to MBP_shortPPII_ErbB2. Recombinant SH3 domains carrying mutations in the three main 
interaction sites show impaired binding with PPII-containing recombinant protein, validating the importance 
of these residues for the interaction between SH3 domain and polyproline peptides. Data are represented as 
mean ± SD. ***p < 0.001.
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in BT474 (1 EC50 = 52.3 ± 6.38 μM, 2 EC50 = 239.5 ± 25.98 μM) and in SKBR3 (1 EC50 = 69,8 ± 4.44 μM, 2 
EC50 = 273.9 ± 27.18 μM) cells as shown in Fig. 6B,C. It should be noted that both compounds achieved 50% 
inhibition of proliferation at concentrations below their cytotoxic threshold.
Notably, compound 1 seems to be more effective on the inhibition of cell proliferation in these specific 
cellular models (Fig. 6B,C). Interestingly, these compounds have no significant effect on the proliferation of 
ErbB2-negative HEK 293T cells (Fig. S5), suggesting that the anti-proliferative effect of 1 and 2 in BT474 and 
SKBR3 cells is mainly linked to the inhibition of p130Cas/ErbB2 association, rather than a broad, non-specific 
inhibition of p130Cas-related pathways.
Moreover, results shown in Fig. 6E indicate that compound 1 significantly enhances the efficacy of 
Trastuzumab treatment in SKBR3 cell line, thus suggesting that inhibition of p130Cas-ErbB2 interaction 
could improve Trastuzumab efficacy by decreasing the stability of ErbB2. Consistently, the treatment of SKBR3 
Trastuzumab-resistant cells with compound 1 partially restores the sensitivity of resistant cells to Trastuzumab 
(Fig. 6F). Our data suggest that the inhibition of ErbB2-p130Cas interaction might impact on both breast cancer 
cell proliferation and resistance to Trastuzumab, opening up new therapeutic perspectives.
ADME-Tox prediction. To explore the future as a drug of 1 and 2 we used free online tools to predict both 
physico-chemical (pKa and log D7.4) and ADME-Tox properties. Data are shown in Table 2. According to pKa 
prediction, both compounds are expected to be in their neutral state at physiological pH and have a similar 
lipophilicity. Although the ADME-Tox profile is globally acceptable, both molecules have defaults. In particular, 
2 is predicted to be poorly permeable (using pkCSM predictor the threshold to distinguish highly from poorly 
permeable compounds is 0.90), whereas 1 is expected to be a substrate of P-glycoprotein which could adversely 
affect the drug candidate effectiveness.
Discussion
Despite the enormous interest in targeting Protein-Protein Interactions (PPIs), the discovery of drugs capable to 
interfere with these interactions has been proven to be very challenging. The transient nature of these interac-
tions, moderate affinity, and promiscuity of recognition are among the many factors that have contributed to dif-
ficulty in discovering effective modulators26–28. Target validation is an essential step in the drug discovery process 
and one of the major causes of attrition. Therefore, the first aim of this study consisted in providing strong support 
for using p130Cas/ErbB2 as a target for the discovery of anticancer drugs.
We reported here, for the first time, that p130Cas association to ErbB2 receptor is indeed direct. In silico sim-
ulations, in vitro data and experiments in 293T cell line support that the direct binding is mediated by the SH3 
domain of p130Cas that recognizes a polyproline type II motif located within the unstructured carboxy-terminal 
tail of the receptor. MD simulations suggest that this polyproline sequence is energetically favored in the inter-
action acting as a ligand for class I SH3 domain. This evidence partially contrasts with data reported in 1995 by 
Polte and Hanks29 showing that the direct binding of SH3 domain of p130Cas with Focal Adhesion Kinase occurs 
through the Pro-rich sequence –APPKPSR- that represents a class II SH3 domain ligand. However, several data 
reported that some SH3 domains (i. e. Src SH3 domain) can bind both class I and class II polyproline peptides30.
In accordance with our results, mutagenesis experiments of key amino acids in the PPII motifs allowed us to 
establish that among the three important residues, the cationic Arg2 residue plays a minor role in the specificity 
of the interaction with the SH3 domain of p130Cas. This led us to hypothesize that the essential “core” for the 
association of polyproline type II peptides with the SH3 domain of p130Cas is the PxxP motif, regardless of the 
position of the charged residue. This in turn might explain why p130Cas can associate through its SH3 domain 
with class I and class II peptides.
The experimental evidence of the direct interaction between p130Cas and ErbB2 is however not sufficient 
to establish whether this protein-protein interaction (PPI) is druggable (i.e. if it could be disrupted by a third 
molecule) or not.
To investigate the druggability of p130Cas/ErbB2 interaction, we firstly performed structure based virtual 
screening using a dataset of small molecules (SMs). This choice is in line with a recent PDB-wide analysis which 
shows that nearly half of all PPIs may be susceptible to SM inhibition31.
Among chemicals predicted to be valuable inhibitors of the investigated interaction we submitted to exper-
imental validation two compounds exhibiting a different binding mode: 1 exploits its action by interacting 
with p130Cas in three regions, whereas the interaction of 2 with p130Cas is driven by hydrogen bonding (HB) 
interactions.
In vitro experiments showed that the two compounds similarly inhibit PPI and suggest that molecules with 
different binding modes could share similar inhibition properties. Conversely, cell line experiments showed that 1 
may stronger slow down cell proliferation in BT474 and SKBR3 cell line (models of ErbB2-overexpressing breast 
tumor) than 2. Permeability prediction could explain this behavior since 1 is expected to be significantly more 
permeable than 2.
We previously demonstrated that high levels of p130Cas expression inversely correlate with ErbB2 sensitivity 
to Trastuzumab probably by binding to ErbB2 and increasing its stability to the cell membrane5.
Interestingly, a small molecule inhibitor (compound 1) able to interfere with p130Cas/ErbB2 association 
synergized with Trastuzumab treatment in Trastuzumab-sensitive SKBR3 cells, thus suggesting that inhibition 
of p130Cas-ErbB2 interaction might be used to improve Trastuzumab efficacy. Notably, this beneficial effect 
was also observed in Trastuzumab-resistant cells, in which compound 1 partially restores their sensitivity to 
Trastuzumab. These effects might rely on the ability of compound 1 to interfere with p130Cas/ErbB2 association, 
thus reducing p130Cas-mediated ErbB2 stabilization at the cell membrane5. These results strongly enforce the 
hypothesis that the increased stabilization of ErbB2 by p130Cas might be a crucial event driving breast cancer 
progression and resistance to antibody-based anti-ErbB2 therapies, opening new therapeutic alternatives.
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In this regard, a medicinal chemistry effort is required to optimize compounds’ potency. To this end, virtual 
libraries of analogues of 1 and 2 will be obtained, screened for their activity using structure-based virtual screen-
ing (SBVS) as above, and then filtered based on synthetic accessibility and physicochemical properties. These 
procedures allow to test the most promising candidates in order to find an optimized lead compound.
Overall, this study provides a potential hit compound that through a number of optimization steps could gain 
relevance as an anticancer drug candidate and proposes a strategy to discover small molecules which may target 
protein-protein interactions. It is worth noting that the results reported in this study represent the first attempt to 
translate the current large knowledge on p130Cas, and its contribution to breast cancer progression, into some-
thing that may be employed as therapeutic agent in the future.
Experimental Section
Cloning of p130Cas. Coding sequence for p130Cas SH3 domain (3–71) (named SH3_p130Cas) was 
amplified from cDNA with PCR using 5′-GGATCCCACCTGAACGTGCTGGC-3′ forward primer and 
5′-GCGGCCGCCTATTATGGCTTCTTATCATACA-3′ reverse primer and cloned in-frame into pGEX-4T3 
vector using BamHI and NotI restriction sites.
Figure 4. Structure-based virtual screening identifies compounds with potential inhibitory properties. (A) 
Chemical structures of two high ranked compounds from the SBVS: ZINC84136897 (1) and ZINC39121740 
(2). (B) Binding mode of 1 (left panel) and 2 (right panel) with SH3_p130Cas. The selected compounds 
showed different binding modalities since 1 exploits its action by interacting with SH3_p130Cas in three 
regions, whereas the interaction of 2 with SH3_p130Cas is driven by hydrogen bonding (HB) interactions. (C) 
Fluorescence quenching spectra of the complex Fl-GST_SH3_p130Cas (0.07 μM) in the absence and presence 
of 1 (0, 0.07, 0.21, 0.7, 3.5, 7.0, 14, 21 μM) (left panel) and in the absence and presence of 2 (0, 2.1, 3.5, 5.5, 7.0, 
10, 15, 21 μM) (right panel) demonstrating the binding between the selected compounds and the target protein.
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Figure 5. Screened compounds inhibit GST_SH3_p130Cas/MBP_shortPPII_ErbB2 association in vitro. (A) 
Competitive ELISA binding assay was performed to validate two high ranked selected compounds (1 and 2) 
as inhibitor of p130Cas/ErbB2 interaction. Both compounds demonstrated dose-dependent inhibition of the 
association between GST_SH3_p130Cas/MBP_shortPPII_ErbB2 purified recombinant proteins in vitro. DPN 
(Diarylpropionitrile) was low-ranked by virtual screening and therefore used as control for non-specific inhibition 
(see Experimental Section). (B) Fluorescence spectra of the complex Fl-GST_SH3_p130Cas/1 (0.01 μM and 3 μM 
respectively) in presence of increasing concentrations of MBP_shortPPII_ErbB2 (0.1, 0.3, 0.5, 0.75 μM (left panel); 
the complex Fl-GST_SH3_p130Cas/2 (0.01 μM and 1 μM respectively) in presence of increasing concentrations 
of MBP_shortPPII_ErbB2 (0.1, 0.3, 0.5, 0.75μM (right panel). (C) Co-immunoprecipitation experiment 
in BT474 cell line. Cells were pre-treated with selected inhibitory compounds for 24 hours and subjected to 
immunoprecipitation with anti-ErbB2 antibodies. Western blot with anti-p130Cas antibodies revealed that both 
compounds were able to reduce the amount of endogenous p130Cas/ErbB2 complex in BT474 cells (upper left 
panel) and quantified by densitometric analysis (right panel). Total cell extracts blotted with anti-ErbB2 and anti-
p130Cas revealed no changes in ErbB2 or p130Cas expression during the treatment (lower left panel). GAPDH 
expression was used as loading control. Data are represented as mean ± SD. **p < 0.01, ***p < 0.001.
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Figure 6. Impact of 1 and 2 compounds on BT474 breast cancer cells. (A) To assess whether 1 and 2 could 
trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile 
DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of 
cytotoxic effects above 75 μM for compound 1. Compound 2 did not show cytotoxic effects even at 250 μM. 
***p < 0.001; ****p < 0.0001. (B) 1 and 2 compounds inhibit cell proliferation of BT474 and (C) SKBR3 breast 
cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed 
three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using 
GraphPad Prism7 software. (D) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are 
represented as histogram with 95% confidence intervals. (E) SKBR3 cells were treated with Trastuzumab (25 μg/
ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells 
were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. (D) SKH100 
Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with 
compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data 
are represented as mean ± SD. *p < 0.05, **p < 0.01.
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pGEX vectors containing p130Cas substrate domain (named YXXP_p130Cas) and p130Cas carboxy-terminal 
domain (named CT_p130Cas) were engineered by Prof. Emilia Turco, MBC, University of Torino. All PCR 
amplifications and cloning procedures were verified by Sanger sequencing.
Cloning of ErbB2. Two different ErbB2 constructs containing the putative polyproline domain (named 
shortPPII_ErbB2 and longPPII_ErbB2) were amplified from ErbB2 cDNA and cloned in-frame in pMAL-C2 
vector for recombinant protein production and in pEGFP-C2 vector for 293T transfection, using SacI and SalI 
restriction sites.
Expression and purification of recombinant proteins. pGEX-4T3 and pMAL-C2 engineered vectors 
were purified using commercial silica column and transformed into competent BL21 bacteria for expression of 
recombinant fusion proteins. MBP and GST fusion proteins were produced in Escherichia coli BL21 bacteria strain 
together with GST and MBP proteins alone (GST_ctrl and MBP_ctrl, respectively) as controls and then purified 
on a Sepharose amylose (New England Biolabs) or Sepharose glutathione column (GE Healthcare) according to 
the manufacturer’s instructions. After elution step all recombinant proteins were dialyzed two times against PBS 
at 4 °C, aliquoted and stored at −80 °C. See Table 1 for recombinant proteins details.
Site directed mutagenesis. Site directed mutagenesis of shortPPII_ErbB2 sequence (in pMAL-C2 and 
pEGFP-C2 vectors) was performed with QuickChange Site-Directed Mutagenesis Kit (Agilent) following manu-
facturer instructions. Mutagenic primers were the same for both plasmids (Table S1).
Mutants of shortPPII_ErbB2 protein in pMAL-C2 vector were expressed, purified and quantified as reported 
above. See Table 1 for recombinant protein details.
Site directed mutagenesis of SH3_p130Cas sequence (in pGEX-4T3 vector) was performed with QuickChange 
Site-Directed Mutagenesis Kit (Agilent) following manufacturer instructions. Mutagenic primers were reported 
(Table S1). Mutants of SH3_p130Cas protein in pGEX-4T3 vector were expressed, purified and quantified as 
reported above.
Antibodies. Mouse monoclonal antibodies to human p130Cas were produced in our department (see5) 
Additional mouse monoclonal p130Cas antibodies were purchased from BD Transduction Laboratory (Franklin 
Lakes, NJ, USA) (Material number 610272). Antibodies to GST (mouse monoclonal), MBP (rabbit polyclonal) 
and GFP (mouse monoclonal and rabbit polyclonal) tags were produced at the MBC, University of Torino. 
Additional rabbit polyclonal antibodies to GST, MBP and GFP tags were obtained from Thermo Scientific (cata-
log # A-5800) and Sigma Aldrich (catalog #M1321 and # G1544).
Dot blot binding assay. For dot blot experiments, 1 μl of GST-tagged p130Cas purified recombinant pro-
teins was manually spotted onto nitrocellulose and let air-dry for 30 minutes at room temperature. Saturation 
was performed using 5% BSA in TBS-0.3% Tween20 at room temperature for 3 hours. After 3 washing steps with 
TBS-0.3% Tween20, nitrocellulose filters were incubated with MBP-tagged ErbB2 purified recombinant proteins 
(1 μg/ml) in Interaction Buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 1%Triton-X100) at 4 °C overnight. The 
day after, nitrocellulose filters were washed twice with Interaction Buffer and twice with TBS-0.3% Tween20. 
The interacting proteins were detected using rabbit polyclonal anti-MBP antibody and peroxidase conjugated 
anti-rabbit secondary antibody with chemoluminescent ECL reagent.
Nitrocellulose filters were then extensively washed with TBS-0.3% Tween20 and incubated overnight at 4 °C 
with mouse monoclonal anti-GST antibody and detected by peroxidase conjugated anti-mouse secondary anti-
body. This process revealed the amount of GST-tagged p130Cas purified recombinant proteins that were directly 
spotted onto nitrocellulose.
In vitro binding assay. For the in vitro binding assay, GST-tagged p130Cas and MBP-tagged ErbB2 purified 
recombinant proteins were mixed together in solution (Interaction Buffer with 1% BSA) overnight at 4 °C. The 
day after, standard immunoprecipitation with anti-MBP rabbit polyclonal antibody and proteinA Sepharose (GE 
Healthcare) was performed. After 3 washing steps, proteins were eluted with 2X Laemmli loading buffer. Proteins 
were run on SDS-PAGE under reducing condition, transferred to nitrocellulose and probed with specific antibod-
ies. Interacting partners were revealed using anti-GST mouse monoclonal antibody.
Source 1 2
pKa MoKa 3.44 (b); 9.97 (a) 9.45 (a)
log D7.4 MoKa 1.5 2.0
TPSA ZINC 96 72
permeability pkCSM 1.07 × 10−6 cm/s 0.69 × 10−6 cm/s
P-glycoprotein substrate pkCSM Yes (inhibitor) No
Cyp3A4 substrate pkCSM Yes No
hERG toxicity pkCSM No No
AMES toxicity pkCSM No No
Table 2. Predicted physico-chemical and ADME-Tox properties of the two investigated compounds.
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ELISA. For ELISA binding assay, 100 nM/well of GST_SH3_p130Cas and GST_ctrl purified recombinant pro-
teins were coated to a 96-well microtiter plate in 100 μl of PBS buffer overnight at 4 °C. The day after, washing 
steps and saturation were performed using PBS and 3%BSA in PBS at room temperature. MBP-tagged ErbB2 
purified recombinant proteins and MBP_ctrl (100 nM/well) were added in 100 μl/well of PBS for 2 h. After wash-
ing, anti-MBP mouse monoclonal antibody (0.25 μg/ml) was added for 2 h followed by peroxidase conjugated 
anti-mouse secondary antibody for 1 h. Detection of the protein-protein interaction was revealed by standard 
colorimetric reaction adding 90 μl of chromogenic TMB substrate (3,3′,5,5′-tetramethylbenzidine). The reaction 
was stopped with 90 μl of 0.5 M HCl and absorbance at 450 nM was measured using ELISA plate reader. GST_ctrl 
and MBP_ctrl proteins served as control for non-specific binding between recombinant proteins.
For validation of inhibitory activity of selected compounds, ELISA binding assay was setup as reported 
above. Briefly, 1 and 2 compounds were mixed at various concentration with MBP_shortPPII_ErbB2 purified 
recombinant protein and allowed to interact with pre-absorbed GST_SH3_p130Cas 2 h at room temperature. 
Detection of the protein-protein interaction was revealed as reported above. DPN (Diarylpropionitrile, from 
Sigma Aldrich, catalog number H5915, CAS Number 1428-67-7) was used as control for non-specific inhibition 
of protein-protein interaction32.
Inhibitory compounds. ZINC84136897 (1) and ZINC39121740 (2) were purchased from Enamine Ltd. 
(Kiev, UA) as lyophilized powder and dissolved at 25 mM concentration in 75% DMSO/water. Solubilized chem-
icals were aliquoted and stored at −20 °C protected from light.
Standard MS and H1NMR were performed to validate structure and quality.
Cell cultures. HEK 293T cells (from ATCC, CRL3216) were maintained in DMEM (Thermo Fisher 
Scientific), 10% FBS at 37 °C, 5% CO2 in humidified incubator.
BT474 cells (from ATCC, HTB20) were cultured in DMEM-F12 (Thermo Fisher Scientific), 10% FBS at 37 °C, 
5% CO2 in humidified incubator.
SKBR3 cells were cultured in McCoy’s 5 A (Thermo Fisher Scientific), 15% FBS at 37 °C, 5% CO2 in humidi-
fied incubator.
SKBR3 resistant cells (SKH100) made resistant to Trastuzumab were generated by Dr. Valabrega and main-
tained as described in33.
All used cell lines were authenticated in the last 6 months by BMR Genomics (Padova, Italy), using the CELL 
ID System (Promega, Madison, WI).
All cells were regularly checked for mycoplasma contamination by specific PCR.
293T transfection. For transfection of pEGFP-C2 vectors containing GFP-tagged ErbB2 constructs, 293T 
cells were seeded in 10-cm dishes at 5 × 106 cells/dish. After cells reached 90–95% confluence, plasmid vectors 
(8 μg/dish) with Lipofectamine 2000 (Invitrogen Inc.) were transfected into 293T cells following manufacturer 
instructions.
Cytotoxicity assay. For cytotoxicity assay BT474 cells were seeded at 5000 cells/well concentration (100% 
confluency) in a 96-well cell culture plate and incubated with serial dilutions of 1 and 2 compounds (from 250 μM 
to 0.12 μM). Cytotoxicity was evaluated after 3 days by MTT assay (11465007001 Roche, Cell Proliferation Kit I) 
following manufacturer instruction.
Cell proliferation assay. For proliferation assay BT474, SKBR3 and SKH100 cells were seeded in 8 repli-
cates at 1000 cells/well concentration (25% confluency) in four different 96-well cell culture plates and then incu-
bated with increasing concentration of 1 and 2 for 3 days. Changes in proliferation rate were detected by MTT 
assay (11465007001 Roche, Cell Proliferation Kit I) following manufacturer instruction. Sterile DMSO was used 
as control for non-specific solvent effect on proliferation.
Statistical analysis. All the results are representative of at least three independent experiments performed 
in triplicate.
All data obtained on protein-protein interaction were normalized using GST_ctrl and MBP_ctrl as 
non-specific control. Data obtained from ELISA and MTT assays using 1 and 2 were normalized using either 
DPN or DMSO as non-specific control.
Statistical analysis of data obtained from ELISA and MTT assays was performed using 2-way ANOVA 
corrected for multiple comparison by Tukey test. p-value < 0.05 (95% confidence interval) were considered 
significant.
Fluorescence quenching experiments. All fluorescence spectra were recorded with a Horiba Jobin Yvon 
Fluorolog3 TCSPC spectrofluorophotometer with 1.0 cm quartz cells
For fluorescence experiments, GST_SH3_p130Cas was firstly tagged with fluorescein (Fl-GST_
SH3_p130Cas) using a methodology described in the literature34 see Supporting Information). The fluorescence 
spectra of Fl-GST_SH3_p130Cas were obtained using a fixed concentration of 3.0 μM in the absence and in 
the presence of MBP_shortPPII_ErbB2 (concentration range: 0.05–3.0 μM). Fluorescence emission spectra of 
Fl-GST_SH3_p130Cas in the presence of 1 and 2 were obtained using the following concentrations: Fl-GST_
SH3_p130Cas = 0.7 μM; 1 and 2  = 0–21 μM. Finally, MBP_shortPPII_ErbB2 (concentration range: 0–75 μM) 
was added to the complexes between Fl-GST_SH3_p130Cas and the two compounds.
The variation in fluorescence emission at 518 nm of Fl-GST_SH3_p130Cas was monitored in all experiments.
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Computational section. In this study, we used two crystallographic structures: the SH3 domain of p130Cas 
(PDB code 1WYX) and the SH3 domain of p85 in complex with the peptide PD1R (PDB code 3I5R). Both 
structures were downloaded from the Protein Data Bank (www.rcsb.org).The ErbB2 sequence was submitted to 
Eukaryotic Linear Motif (ELM) (www.elm.org)18 by using the FASTA format as an input.
The interaction complex SH3_p130Cas/PPII_ErbB2 was built with MOE version 2010.10 (www.chemcomp.
com).
The virtual screening for inhibitors of the SH3_p130Cas/PPII_ErbB2 interaction has been performed by 
FLAP version 2.0.2 (www.moldiscovery.com). The screening has been made over the 15 million compound subset 
“drug-like clean” of the ZINC database v.13 (www.zinc.docking.com).
Preparation of the complex SH3_p130Cas/PPII_ErbB2. Two starting structures were downloaded 
from the Protein Data Bank (www.rcsb.org): the SH3 domain of p130Cas (PDB code 1WYX) and the SH3 
domain of p85 in complex with the peptide PD1R (PDB code 3I5R). 1WYX and 3I5R were imported in MOE 
(ver. 2016.08, www.chemcomp.com).
Firstly, PD1R 3D structure was extracted from 3I5R. Four amino acids, i.e. K, L, L and S, present in the 
PD1R sequence (KRPLPPLPS) were mutated into V, Q, S and R, respectively, to obtain PPII_ErbB2 model 
(VRPQPPSPR).
The structure of the SH3 domain of p130Cas was prepared starting from 1WYX: one monomer was retained, 
and water molecules and ions were removed. The structure was then protonated using MOE Protonate3D 
(T = 310,15 K, pH = 6,8, I.F. = 0,2 mM). The same procedure was applied to the SH3 domain of p85 present in 
the pdb file 3I5R.
Finally, the structure of the complex SH3_p130Cas/PPII_ErbB2 was obtained through alignment and super-
position of SH3_p130Cas and PPII_ErbB2 with the SH3 domain of p85 and PD1R, respectively.
The complex was minimized using the CHARM22 force field (RMS gradient less than 0.001 kcal mol−1 Å−2).
Molecular Dynamics simulations. All steps of MD simulations were set up using the BiKi Life Science 
software (default settings for plain MD simulations, ver. 1.3.5, http://www.bikitech.com/) which provides an 
intuitive GUI interface to GROMACS and Amber tools. In particular, the setup of the simulations is based on 
Antechamber software (ver. 14, http://ambermd.org/antechamber/ac.html) whereas MD simulations were per-
formed with GROMACS (ver.4.6.1, http://www.gromacs.org/) package using the Amber ff14 force field35. Water 
molecules were described using the TIP3P model36 and periodic boundary conditions were applied. The system 
was neutralized by adding a sodium ion.
The solvated system was minimized using a steepest descent minimization (the maximum number of min-
imization cycles was set to 5000). Equilibration was carried out in four steps: firstly, three 100 ps NVT simula-
tions were performed to gradually increase the temperature up to the final 300 K, then one 1 ns NPT step was 
carried out to allow the system to stably reach the pressure condition of 1 atm. Finally, one 50 ns MD production 
run was performed with a time step for integration equal to 0.002 ps and a number of steps equal to 25000000. 
Coordinates were saved every 10 ps; in total 5000 snapshots were obtained. The temperature coupling was done 
using a velocity rescaling with a stochastic term that ensures that a proper canonical ensemble is generated37.
Dataset preparation. The subset of compounds named “Clean Drug-Like” was downloaded from the ZINC 
database (ver. 13, www.zinc.docking.org). This subset contains about 15 million of molecules which were filtered 
by applying the following criteria: (a) Lipinski’s rules of five (i.e. no more than 5 hydrogen bond donors and 10 
hydrogen bond acceptors, a molecular mass less than 500 Daltons, ClogP less than 5), (b) molecular mass greater 
than 150 Daltons, (c) number of rotatable bonds lower than 7, (d) formal charge in the range [−2; +2].
Structure based virtual screening (SBVS). The SH3_p130Cas/PPII_ErbB2 structure was imported in 
FLAP (v. 2.2.1, www.moldiscovery.com) and the interface between the protein and the peptide was used to define 
the pocket for the SBVS (Pocket Point Radius = 2 Å). MIFs with the default probes DRY, O, N1, and H were calcu-
lated for the residues in the pocket and FLAP fingerprints for SH3_p130Cas were generated38.
The compounds resulting from the previous step were submitted to FLAP in their ionization state at pH = 7. 
FLAP generates 25 low energy conformers for each compound. For each of these conformations, the molecular 
interaction fields (MIFs) for H, O, N1, and DRY GRID probes were calculated at a 0.75 Å grid resolution, and 
FLAP fingerprints were generated. To reduce the number of molecules in the dataset, a quick pre-filtering run was 
performed using the implemented procedure in the bit-string mode. The Glob-Sum similarity score was used to 
rank the compounds in the dataset and the 10000 compounds with the higher score were retained.
Finally, the reduced dataset was screened against the SH3_p130Cas model scoring the complementarity 
between the candidate and the protein pocket. The Glob-Prod similarity was used to rank the molecules in the 
dataset.
Physico-chemical and ADME-Tox prediction. For calculating pKa and log D7.4 we used MoKa v. 2.6.5 
(www.moldiscovery.com). To predict the pharmacokinetic profile of 1 and 2 we used pkCSM (http://biosig.uni-
melb.edu.au/pkcsm/), a free Web tool, properly documented in the literature39.
All calculations were run on an Aethia EXA-W 4 core Xeon workstation.
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